Compare Fastly Inc (FSLY) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fastly Inc vs Repligen Corporation Common Stock — how do they compare? Fastly Inc trades at $24.5 (market cap $4.32B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 2.6× Fastly Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Fastly Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fastly Inc for 26 Days and Repligen Corporation Common Stock for 0 Days on average.
| FSLY | RGEN | |
|---|---|---|
Market Cap | $4.32B | $11.14B |
Volume | 5,665,889 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $33.50 | $194.57 |
52-Week Low | $7.86 | $102.87 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $4.38B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fastly (FSLY) trades at $25.00, down 5.41% over the past day, with a bullish technical signal from moving averages and support at $25. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.15 exceeding expectations, while revenue growth is robust at 23% year-over-year. However, net income remains negative, and cash flow trends show volatility, with a net outflow of $105.61 million in 2025. Recent news highlights insider selling by the CTO but also positive coverage of AI-driven growth potential.
The outlook for FSLY is mixed, with opportunities from AI infrastructure demand and revenue targets up to $1.3 billion by 2029, but risks include persistent losses, high valuation multiples, and competitive pressures. Analyst consensus is a 'Hold' with a $28.33 price target, suggesting limited near-term upside from current levels amid execution challenges.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Read more on FSLY →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
